Document is current
Any future updates will be listed below
-
Authors
Adachi, Yoshitaka https://orcid.org/0000-0002-9763-5533
Terakura, Seitaro https://orcid.org/0000-0002-1194-8046
Osaki, Masahide
Okuno, Yusuke https://orcid.org/0000-0003-3139-9272
Sato, Yoshitaka https://orcid.org/0000-0002-8541-6413
Sagou, Ken
Takeuchi, Yuki
Yokota, Hirofumi https://orcid.org/0009-0005-8979-5181
Imai, Kanae
Steinberger, Peter https://orcid.org/0000-0001-6848-4097
Leitner, Judith https://orcid.org/0000-0002-7156-1759
Hanajiri, Ryo
Murata, Makoto https://orcid.org/0000-0001-5488-4364
Kiyoi, Hitoshi https://orcid.org/0000-0001-6382-9498
- License Information
-
More Information
Article History
Received: 23 March 2023
Accepted: 21 November 2024
First Online: 10 December 2024
Competing interests
: Y. Adachi, S. Terakura, and H. Kiyoi are inventors on patent applications for CUL5 modification technologies submitted by Nagoya University, Nagoya, Japan. H. Kiyoi has received research funding from FUJIFILM, Kyowa-Kirin, Bristol-Myers Squibb, Otsuka, Perseus Proteomics, Daiichi Sankyo, Abbvie, CURED, Astellas Pharma, Chugai, Zenyaku Kogyo, Nippon Shinyaku, Eisai, Takeda, Sumitomo Pharma, and Sanofi, in addition to honoraria from Abbvie, Chugai, Astellas Pharma, and Novartis. The other authors declare no competing financial or non-financial interests.
